The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and tolerability of high dose interleukin-2 (HD IL-2) after disease progression on targeted therapy (TT) for metastatic renal cell carcinoma (mRCC).
 
Peter Vu
No Relationships to Disclose
 
Hanh P. Mai
No Relationships to Disclose
 
William Adams
No Relationships to Disclose
 
Beverly Gonzalez
No Relationships to Disclose
 
Stephanie Kliethermes‌
No Relationships to Disclose
 
Joseph Clark
Honoraria - Bristol-Myers Squibb; Merck; Pfizer; Prometheus
Consulting or Advisory Role - Argos Therapeutics; Bayer; Prometheus
Speakers' Bureau - Argos Therapeutics; Bayer; Prometheus
Research Funding - Argos Therapeutics; Bristol-Myers Squibb; Pfizer; Prometheus
 
Elizabeth Henry
No Relationships to Disclose